Epcoritamab(一种新型皮下CD3xCD20双特异性T细胞衔接抗体)治疗复发或难治性大B细胞淋巴瘤:I/II期试验剂量扩展
这项I/II期研究剂量扩展队列纳入157例复发或难治性CD20+大B细胞淋巴瘤成人患者,接受皮下Epcoritamab治疗。中位随访10.7个月时,总缓解率为63.1%(95%CI 55.0-70.6),完全缓解率为38.9%(95%CI 31.2-46.9),中位缓解持续时间12.0个月。常见治疗中出现的不良事件为细胞因子释放综合征(49.7%)、发热(23.6%)和乏力(22.9%)。
要点
- 皮下Epcoritamab在高度难治性大B细胞淋巴瘤中总缓解率63.1%、完全缓解率38.9%。
- 中位缓解持续时间12.0个月,完全缓解者中位缓解持续时间未达到。
- 细胞因子释放综合征发生率49.7%,多为1-2级(47.1%),3级为2.5%。
核心结论
- 皮下Epcoritamab在高度难治性大B细胞淋巴瘤患者(包括既往暴露于CAR T细胞者)中产生深度且持久的缓解,安全性可控。
研究设计与样本
- I/II期研究(ClinicalTrials.gov标识符:NCT03625037)的剂量扩展队列。
- 纳入157例复发或难治性CD20+大B细胞淋巴瘤成人患者,既往至少接受过二线治疗(包括抗CD20治疗)。
- 皮下注射Epcoritamab,28天为一周期:第1周期第1-3周每周一次递增剂量,此后至第3周期每周一次全剂量,第4-9周期每2周一次,第10周期及以后每4周一次,直至疾病进展或不可接受的毒性。
- 主要终点为独立审查委员会评估的总缓解率。
主要发现
- 截至2022年1月31日,157例患者接受治疗,中位年龄64岁(范围20-83),中位既往治疗线数3线(范围2-11),原发难治性疾病占61.1%,既往CAR T细胞暴露占38.9%。
- 中位随访10.7个月时,总缓解率为63.1%(95%CI 55.0-70.6),完全缓解率为38.9%(95%CI 31.2-46.9)。
- 中位缓解持续时间为12.0个月,完全缓解者中位缓解持续时间未达到。
- 总缓解率和完全缓解率在关键预设亚组间相似。
- 最常见的治疗中出现的不良事件为细胞因子释放综合征(49.7%;1级或2级47.1%;3级2.5%)、发热(23.6%)和乏力(22.9%);免疫效应细胞相关神经毒性综合征发生率为6.4%,其中1例为致死性事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Epcoritamab is a subcutaneously administered CD3xCD20 T-cell-engaging, bispecific antibody that activates T cells, directing them to kill malignant CD20+ B cells. Single-agent epcoritamab previously demonstrated potent antitumor activity in dose escalation across B-cell non-Hodgkin lymphoma subtypes. PATIENTS AND METHODS: In the dose-expansion cohort of a phase I/II study (ClinicalTrials.gov identifier: NCT03625037), adults with relapsed or refractory CD20+ large B-cell lymphoma and at least two prior therapy lines (including anti-CD20 therapies) received subcutaneous epcoritamab in 28-day cycles (once weekly step-up doses in weeks 1-3 of cycle 1, then full doses once weekly through cycle 3, once every 2 weeks in cycles 4-9, and once every 4 weeks in cycle 10 and thereafter) until disease progression or unacceptable toxicity. The primary end point was overall response rate by the independent review committee. RESULTS: As of January 31, 2022, 157 patients were treated (median age, 64 years [range, 20-83]; median of three [range, 2-11] prior therapy lines; primary refractory disease: 61.1%; prior chimeric antigen receptor (CAR) T-cell exposure: 38.9%). At a median follow-up of 10.7 months, the overall response rate was 63.1% (95% CI, 55.0 to 70.6) and the complete response rate was 38.9% (95% CI, 31.2 to 46.9). The median duration of response was 12.0 months (among complete responders: not reached). Overall and complete response rates were similar across key prespecified subgroups. The most common treatment-emergent adverse events were cytokine release syndrome (49.7%; grade 1 or 2: 47.1%; grade 3: 2.5%), pyrexia (23.6%), and fatigue (22.9%). Immune effector cell-associated neurotoxicity syndrome occurred in 6.4% of patients with one fatal event. CONCLUSION: Subcutaneous epcoritamab resulted in deep and durable responses and manageable safety in highly refractory patients with large B-cell lymphoma, including those with prior CAR T-cell exposure.
引用
- Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. J Clin Oncol. 2022. PMID: 36548927. doi:10.1200/JCO.22.01725
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。